[
    [
        {
            "time": "2020-06-14",
            "original_text": "贝达药业:2.51亿元出售贝达医药科技全部股权 资产异常",
            "features": {
                "keywords": [
                    "贝达药业",
                    "出售",
                    "贝达医药科技",
                    "股权",
                    "2.51亿元"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业:2.51亿元出售贝达医药科技全部股权 资产异常",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-06-14",
            "original_text": "贝达药业(300558.SZ)：拟向实控人控制的公司出售贝达医药科技全部股权 控制人变化",
            "features": {
                "keywords": [
                    "贝达药业",
                    "实际控制人",
                    "出售",
                    "贝达医药科技",
                    "股权"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：拟向实控人控制的公司出售贝达医药科技全部股权 控制人变化",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-06-14",
            "original_text": "贝达药业：2.5亿元出售全资子公司贝达医药科技",
            "features": {
                "keywords": [
                    "贝达药业",
                    "出售",
                    "全资子公司",
                    "贝达医药科技",
                    "2.5亿元"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业：2.5亿元出售全资子公司贝达医药科技",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-06-14",
            "original_text": "贝达药业(300558.SZ)：贝伐珠单抗注射液(MIL60)上市许可申请获得受理",
            "features": {
                "keywords": [
                    "贝达药业",
                    "贝伐珠单抗注射液",
                    "MIL60",
                    "上市许可",
                    "申请受理"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：贝伐珠单抗注射液(MIL60)上市许可申请获得受理",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]